Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies

Pharmacology and Therapeutics

Volumn 157, Issue , 2016, Pages 120-124

  Esposito, Angela ^a   Criscitiello, Carmen ^a   Locatelli, Marzia ^a   Milano, Monica ^a   Curigliano, Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Circulating tumor DNA; Disease monitoring; Early detection; Intra tumor heterogeneity; Liquid biopsy; Molecular resistance

Indexed keywords

B RAF KINASE; CA 15-3 ANTIGEN; CETUXIMAB; CHLOROPLAST DNA; ERLOTINIB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; N RAS PROTEIN; PHOSPHOINOSITIDE 3 KINASE CATALYTIC ALPHA PROTEIN; PROTEIN; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; DNA;

ADVANCED CANCER; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL; CANCER RECURRENCE; CANCER RESISTANCE; CIRCULATING TUMOR CELL; CODON; DNA METHYLATION; EARLY DIAGNOSIS; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; LIQUID BIOPSY; LIVER CELL CARCINOMA; MELANOMA; METASTATIC COLORECTAL CANCER; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; OVARY CANCER; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; SOLID TUMOR; SOMATIC MUTATION; TUMOR BIOPSY; BIOPSY; DRUG RESISTANCE; GENETICS; NEOPLASMS; PATHOLOGY; TUMOR EMBOLISM;

ANTINEOPLASTIC AGENTS; BIOPSY; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84952638610     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.11.007     Document Type: Review

References (38)

1. J.A. Beaver, D. Jelovac, S. Balukrishna, R.L. Cochran, S. Croessmann, D.J. Zabransky, and et al. Detection of cancer DNA in plasma of early stage breast cancer patients Clin Cancer Res 20 2014 2643 2650
2. C. Bettegowda, M. Sausen, R.J. Leary, I. Kinde, Y. Wang, N. Agrawal, and et al. Detection of circulating tumor DNA in early- and late-stage human malignancies Sci Transl Med 6 224 Feb 19, 2014 224ra24
3. K.C. Chan, P. Jiang, Y.W. Zheng, G.J. Liao, H. Sun, J. Wong, and et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing Clin Chem 59 2013 211 224
4. Z. Chen, J. Feng, C.H. Buzin, Q. Liu, L. Weiss, K. Kernstine, and et al. Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non metastatic breast cancer PLoS One 4 9 Sep 28, 2009 e7220
5. S.J. Dawson, D.W. Tsui, M. Murtaza, H. Biggs, O.M. Rueda, S.F. Chin, and et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer N Engl J Med 368 13 Mar 28, 2013 1199 1209
6. L. De Mattos-Arruda, B. Weigelt, J. Cortes, H.H. Won, C.K. Ng, P. Nuciforo, and et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle Ann Oncol 25 9 Sep. 2014 1729 1735
7. W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas, and et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
8. L.A. Diaz Jr., R.T. Williams, J. Wu, I. Kinde, J.R. Hecht, J. Berlin, and et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 2012 537 540
9. F. Diehl, He Y. LiM, Vogelstein B. KinzlerKW, and D. Dressman BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions Nat Methods 3 2006 551 559
10. F. Diehl, K. Schmidt, M.A. Choti, K. Romans, S. Goodman, M. Li, and et al. Circulating mutant DNA to assess tumor dynamics Nat Med 14 2008 985 990
11. A. Esposito, A. Bardelli, C. Criscitiello, N. Colombo, L. Gelao, L. Fumagalli, and et al. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities Cancer Treat Rev. 40 5 Jun. 2014 648 655
12. T. Forshew, M. Murtaza, C. Parkinson, D. Gale, D.W. Tsui, F. Kaper, and et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA Sci Transl Med 4 136 May 30, 2012 136ra68
13. I. Garcia-Murillas, G. Schiavon, B. Weigelt, C. Ng, S. Hrebien, R.J. Cutts, and et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer Sci Transl Med 7 302 Aug 26, 2015 302ra133
14. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, and et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
15. S. Jahr, H. Hentze, S. Englisch, D. Hardt, F.O. Fackelmayer, R.D. Hesch, and et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells Cancer Res 61 2001 1659 1665
16. I. Kinde, J. Wu, N. Papadopoulos, K.W. Kinzler, and B. Vogelstein Detection and quantification of rare mutations with massively parallel sequencing Proc Natl Acad Sci U S A 108 2011 9530 9535
17. C.A. Klein, S. Seidl, K. Petat-Dutter, S. Offner, J.B. Geigl, O. Schmidt-Kittler, and et al. Combined transcriptome and genome analysis of single micrometastatic cells Nat Biotechnol 20 2002 387 392
18. M.G. Krebs, R.L. Metcalf, L. Carter, G. Brady, F.H. Blackhall, and C. Dive Molecular analysis of circulating tumour cells - biology and biomarkers Nat Rev Clin Oncol 11 2014 129 144
19. R.J. Leary, M. Sausen, I. Kinde, N. Papadopoulos, J.D. Carpten, D. Craig, and et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing Sci Transl Med 4 162 Nov 28, 2012 162ra154
20. R. Lebofsky, C. Decraene, V. Bernard, M. Kamal, A. Blin, Q. Leroy, and et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types Mol Oncol 9 4 Apr. 2015 783 790
21. S.A. Leon, B. Shapiro, D.M. Sklaroff, and M.J. Yaros Free DNA in the serum of cancer patients and the effect of therapy Cancer Res 37 1977 646 650
22. Q. Liu, and S.S. Sommer Pyrophosphorolysisactivated polymerization (PAP): application to allele specific amplification Biotechniques 29 2000 1072 1076 (1078, 1080)
23. D.J. McBride, A.K. Orpana, C. Sotiriou, H. Joensuu, P.J. Stephens, L.J. Mudie, and et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors Genes Chromosomes Cancer 49 2010 1062 1069
24. S. Misale, S. Arena, S. Lamba, G. Siravegna, A. Lallo, S. Hobor, and et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer Sci Transl Med 6 2014 224ra26
25. S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Liska, and et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 7404 Jun 28, 2012 532 536
26. M. Murtaza, S.J. Dawson, D.W. Tsui, D. Gale, T. Forshew, A.M. Piskorz, and et al. Non invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA Nature 497 2013 108 112
27. G.R. Oxnard, C.P. Paweletz, Y. Kuang, S.L. Mach, A. O'Connell, M.M. Messineo, and et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA Clin Cancer Res 20 2014 1698 1705
28. G. Perkins, T.A. Yap, L. Pope, A.M. Cassidy, J.P. Dukes, R. Riisnaes, and et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers PLoS One 7 11 2012 e47020
29. T. Reinert, L.V. Schøler, R. Thomsen, H. Tobiasen, S. Vang, and Nordentoft Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery Gut Feb 4, 2015 10.1136/gutjnl-2014-308859 (pii: gutjnl-2014-308859 [Epub ahead of print])
30. H. Schwarzenbach, C. Eichelser, J. Kropidlowski, W. Janni, B. Rack, and K. Pantel Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression Clin Cancer Res 18 2012 5719 5730
31. H. Schwarzenbach, D.S. Hoon, and K. Pantel Cell-free nucleic acids as biomarkers in cancer patients Nat Rev Cancer 11 6 2011 426 437
32. B. Shapiro, M. Chakrabarty, E.M. Cohn, and S.A. Leon Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease Cancer 51 1983 2116 2120
33. G. Siravegna, B. Mussolin, M. Buscarino, G. Corti, A. Cassingena, G. Crisafulli, and et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients Nat Med 21 7 Jul. 2015 795 801
34. M. Stroun, P. Maurice, V. Vasioukhin, J. Lyautey, C. Lederrey, and F. Lefort The origin and mechanism of circulating DNA Ann N Y Acad Sci 906 2000 161 168
35. T.K. Sundaresan, and D.A. Haber Does molecular monitoring matter in early-stage breast cancer? Sci Transl Med 7 302 Aug 26, 2015
36. C. Swanton Intratumor heterogeneity: evolution through space and time Cancer Res 72 2012 4875 4882
37. V. Taly, D. Pekin, A.A. El, and P. Laurent-Puig Detecting biomarkers with microdroplet technology Trends Mol Med 18 2012 405 416
38. K.S. Thress, C.P. Paweletz, E. Felip, B.C. Cho, D. Stetson, B. Dougherty, and et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M Nat Med 21 6 Jun. 2015 560 562